Clinical Trial: Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed AML

VIDEO | 03:00

Intensive chemotherapy is one way of treating acute myeloid leukemia (AML), but many older adults have difficulty tolerating the side effects. Memorial Sloan Kettering hematologist-oncologist Ellin Berman discusses a study that evaluates the safety and effectiveness of the investigational drug sapacitabine in patients age 70 and older who are newly diagnosed with AML.